The Oncology Institute, Inc. (NASDAQ:TOI) Short Interest Up 86.8% in January

The Oncology Institute, Inc. (NASDAQ:TOI) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 324,100 shares, an increase of 86.8% from the December 31st total of 173,500 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is currently 0.2 days.

Insider Activity

In other news, Director Brad Hively purchased 250,000 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were purchased at an average price of $0.17 per share, with a total value of $42,500.00. Following the purchase, the director now directly owns 616,753 shares of the company’s stock, valued at $104,848.01. This trade represents a 68.17 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 9.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Oncology Institute

A hedge fund recently raised its stake in Oncology Institute stock. Renaissance Technologies LLC increased its stake in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 142.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 339,400 shares of the company’s stock after buying an additional 199,300 shares during the period. Renaissance Technologies LLC owned 0.46% of Oncology Institute worth $156,000 as of its most recent filing with the SEC. Institutional investors own 36.86% of the company’s stock.

Oncology Institute Stock Up 6.3 %

TOI traded up $0.05 on Wednesday, hitting $0.84. 506,698 shares of the company were exchanged, compared to its average volume of 932,877. The company has a debt-to-equity ratio of 5.91, a quick ratio of 2.27 and a current ratio of 2.49. The stock’s fifty day moving average is $0.31 and its 200-day moving average is $0.35. The company has a market cap of $63.47 million, a PE ratio of -1.08 and a beta of 0.13. Oncology Institute has a 12 month low of $0.13 and a 12 month high of $2.23.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.